What Is Retatrutide (LY3437943)?

Short definition

Retatrutide is an investigational peptide. In the scientific literature it also appears as LY3437943. The Phase 2 trial published in The New England Journal of Medicine describes it as an agonist of the GIP, GLP-1, and glucagon receptors.³

This page answers the identity question: what the compound is, who developed it, and what sits outside that definition. Receptor detail is in how retatrutide works. The trial program is in retatrutide clinical trials.

Retatrutide and LY3437943

LY3437943 is Eli Lilly’s development code. The 2022 Cell Metabolism discovery paper presents the compound under that code. The 2023 NEJM Phase 2 trial uses the name retatrutide together with LY3437943. Both identifiers refer to the same peptide in the sources cited here.^1,3

Spanish texts often use retatrutida; English texts use retatrutide. They are not two different molecules. A reader who searches only one name can miss the other half of the literature: the 2022 papers mostly use LY3437943; the 2023 papers already use retatrutide explicitly.

Who developed the compound

Discovery and clinical proof of concept were published by Coskun and colleagues. The Phase 1b trial in people with type 2 diabetes was published by Urva and colleagues. The two Phase 2 trials were published by Jastreboff and colleagues (obesity) and Rosenstock and colleagues (type 2 diabetes).^1,2,3,4

Those papers include authors affiliated with Eli Lilly. That affiliation is stated in the references. It is not hidden, and it is not turned here into a judgment on the paper’s validity.

Lilly is the sponsor of the Phase 3 TRIUMPH trials and the author of the 2026 topline releases.⁸

What “triple agonist” means

In pharmacology, an agonist is a molecule that binds a receptor and can activate the associated signal. “Triple” means the same peptide has been characterized for activity at three different receptors. It does not mean three drugs are given together, and it does not mean the number of targets proves a clinical outcome.¹

Each receptor, and what mechanism cannot conclude, is explained on the mechanism page. This definition stops at the concept.

Which receptors are involved

The three targets described in the discovery work are the GIP receptor (glucose-dependent insulinotropic polypeptide), the GLP-1 receptor (glucagon-like peptide-1), and the glucagon receptor.¹

GIP and GLP-1 are incretins. Glucagon has been studied in energy metabolism, among other contexts. Those labels do not authorize phrases such as “burns fat” or “melts fat.” They also do not turn retatrutide into an approved GLP-1 product.

How the research evolved

In 2022 the discovery account was published, and in the same year a Phase 1b trial in type 2 diabetes.^1,2

In 2023 two distinct Phase 2 trials were published: one in obesity or overweight and one in type 2 diabetes. They are not the same study.^3,4

From 2023, ClinicalTrials.gov lists the Phase 3 TRIUMPH program. Lilly’s 2026 topline announcements belong to that program and are treated on separate pages.

What clinical evidence exists

Phase 1b: Urva and colleagues, The Lancet, 2022, in people with type 2 diabetes.²

Phase 2 obesity: Jastreboff and colleagues, NEJM, 2023; 338 adults; NCT04881760.^3,5

Phase 2 type 2 diabetes: Rosenstock and colleagues, The Lancet, 2023; 281 participants; NCT04867785.^4,6

Phase 3 program: TRIUMPH, with registry records and, for several protocols, sponsor topline announcements. The map is in clinical trials and the current state of those announcements is in what the TRIUMPH studies have reported.

Is it approved?

Lilly has stated an intention to submit a U.S. application in the first quarter of 2027. That is a plan, not an approval or a guaranteed date.^7,8

What it means that it remains investigational

Investigational, in this context, means the compound is being studied in trials and does not have FDA authorization as a medicine. It is not a synonym for “illegal in Mexico” or “approved for laboratory use.” This page does not offer legal advice about Mexico.

The FDA has published U.S. concerns about unapproved retatrutide products marketed to consumers, sometimes with “research only” labels. That source is United States–specific.⁹

What a COA does not show

A certificate of analysis published by Peptra documents analytical results for a Peptra research-material lot. It does not establish that the material was used in Lilly trials, does not demonstrate pharmaceutical equivalence, does not imply FDA approval, and does not indicate suitability for human use.

If you are reviewing a lot, use the Retatrutida certificate archive and the guides on how to read a COA and what 99% purity means.

Next reading

Mechanism: how retatrutide works. Trials: clinical studies. TRIUMPH: Phase 3 results. Index: Retatrutide research hub.